Globally, there are hundreds of thousands of people living with X-linked retinitis pigmentosa, a devastating condition that often leads to vision loss in young people. But a new treatment is giving these patients new hope, and creating a tremendous growth opportunity for the company behind it.
Our guest today is Lance Baldo MD, who has served as the CEO of Beacon Therapeutics since July of 2024. Before Beacon, Lance was chief medical officer at Freenome, where he led medical strategy from clinical trials through registration and commercialization, and Chief Medical Officer at Adaptive Biotechnologies, where he was part of the senior leadership team as it transitioned from a private to a publicly held company.
Lance is also a medical doctor by training, holding an MD from the University of Connecticut School of Medicine, and a BA in biology from Johns Hopkins University.
Today, he joins us to discuss the extremely exciting results of Beacon’s recent medical trials, how they're navigating the regulatory process on the way to launch, and how their novel gene therapy could help patients with a broad array of ocular diseases.
Highlights:
- How Lance Landed the CEO Job (2:29)
- Gene Therapy for the Eye (3:49)
- Who Is Affected by XLRP (4:51)
- A New Hope for Vision Loss (5:38)
- The Day the Trial Results Came In (9:07)
- Why It Took a Decade to Get Here (11:50)
- Reaction From the Scientific Community (13:35)
- Working With Regulators (15:20)
- Getting Ready to Launch (18:04)
- Treating Other Ocular Disorders (20:15)
- Raising Money as a CEO (21:26)
- Priorities for 2027 (26:04)
Feedback:
If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer,
joe@lowerstreet.co
What is Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders?
In the increasingly crowded and competitive corporate and financial ecosystem, it’s harder than ever for companies to break through the clutter and be heard. The media, investors, agenda-driven influencers, even customers and competitors, are defining your business story on their terms. Therefore, it is imperative that companies take control and proactively drive the conversation with stakeholders in an effort to build & maintain equity value.
In Welcome to the Arena from ICR, Co-Founder & Executive Chairman of ICR, Tom Ryan, interviews key business and financial players who influence the fate of public or aspiring public companies in the capital markets. As a former Wall Street Journal ranked sell-side equity analyst and the founder of one of the largest strategic communications firms in the world, Tom understands what it takes to navigate this complex environment.
This is a forum for CEOs, CFOs, institutional investors, sell-side analysts, financial journalists, private equity professionals and other financial community participants to share their stories and give advice in an open and candid conversation.
For more information, visit http://www.icrinc.com